Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 28;11(8):846.
doi: 10.3390/pathogens11080846.

Helicobacter pylori CagA Protein Regulating the Biological Characteristics of Gastric Cancer through the miR-155-5p/SMAD2/SP1 axis

Affiliations

Helicobacter pylori CagA Protein Regulating the Biological Characteristics of Gastric Cancer through the miR-155-5p/SMAD2/SP1 axis

Leilei Wu et al. Pathogens. .

Abstract

Helicobacter pylori (Hp) is a grade Ι carcinogen of gastric cancer (GC), and its high infection rate seriously affects human health. Cytotoxin-associated gene A (CagA) plays a key role in the carcinogenesis of Hp as one of its main virulence factors. miR-155-5p is abnormally expressed in patients with GC, associated with the occurrence and development of cancer. However, little is known about the association between CagA and miR-155-5p. (1) Background: This study explored the association and mechanism of CagA and miR-155-5p in GC. (2) Methods: The CagA sequence was obtained from the NCBI. After sequence optimization, it was connected to the pcDNA3.1 vector to construct a CagA eukaryotic expression plasmid (pcDNA-CagA). Quantitative real-time polymerase chain reaction (qRT-PCR) was used to investigate the expression of miR-155-5p and CagA in GC cells. The function of CagA on GC cells was detected by CCK8, wound healing, and Transwell assays. Similarly, the function of miR-155-5p was also studied through the above functional experiments after the miR-155-5p overexpression and knockdown models had successfully been constructed. The associations among CagA, miR-155-5p, and SMAD2/SP1 were evaluated using RNA immunoprecipitation (RIP) and rescue experiments. (3) Results: The expression of miR-155-5p was significantly reduced in GC cells, and the expression of miR-155-5p was further reduced after CagA induction. Both overexpressed CagA and knockdown miR-155-5p cell models enhanced malignant transformation, whereas overexpressed miR-155-5p inhibited malignant transformation in vitro. The function of miR-155-5p on GC cells could be influenced by CagA. We also found that the influence of miR-155-5p on SMAD2 and SP1 could be regulated by CagA. (4) Conclusions: CagA potentially regulates the biological function of GC cells through the miR-155-5p/SMAD2/SP1 axis. miR-155-5p could be a therapeutic target for GC related to CagA.

Keywords: CagA; SMAD2; SP1; gastric cancer; miR-155-5p.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
The expression of CagA in AGS cells and the effects of CagA overexpression on the biological characteristics of GC AGS cells. (a) qRT-PCR analysis of CagA mRNA expression after treatment with pcDNA-CagA and pcDNA-NC. (b) Western blot analysis of CagA. (c) Assessment of the proliferation of AGS cells transfected with pcDNA-CagA and pcDNA-NC by CCK-8 assay. (d) Wound healing assay to detect the effect of CagA on cell migration. (e) CagA overexpression regulated the migration and invasion of AGS cells. ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Figure 2
Figure 2
The expression of miR-155-5p in AGS cells and the effects of overexpression and knockdown of miR-155-5p on the biological characteristics of AGS. (a,b) qRT-PCR analysis of miR-155-5p mRNA expression after treatment with pcDNA-CagA, miR-155-5p mimics and inhibitor regents. (c,d) Assessment of the proliferation of AGS cells transfected with miR-155-5p mimics and inhibitors by CCK-8 assay. (e) Wound healing assay to detect the effect of miR-155-5p on cell migration. (f) miR-155-5p overexpression and knockdown regulated the migration and invasion of AGS cells. * p < 0.05; ** p < 0.01; *** p < 0.001; **** p < 0.0001.
Figure 3
Figure 3
CagA regulates malignant transformation through miR-155-5p in vitro. (a,b) Co-transfection of miR-155-5p mimics and pcDNA-CagA to investigate malignant transformation of cells with CCK-8 and Transwell assays in the AGS cell line. (c,d) Co-transfection of miR-155-5p inhibitor and pcDNA-CagA to investigate malignant transformation of cells with CCK-8 and Transwell assays in the AGS cell line A: pcDNA-CagA + miR-155-5p mimics NC; B: pcDNA-CagA + miR-155-5p mimics; C: pcDNA-NC + miR-155-5p mimics; D: pcDNA-CagA + miR-155-5p inhibitors NC; E: pcDNA-CagA + miR-155-5p inhibitors; F: pcDNA-NC + miR-155-5p inhibitors; * p < 0.05; *** p < 0.001.
Figure 4
Figure 4
SMAD2 and SP1 were targets of miR-155-5p. (a) qRT-PCR of SMAD2 and SP1 expression in AGS cells transfected with miR-155-5p mimics and inhibitor. (b) RIP assays with anti-SMAD2, anti-SP1, and anti-IgG antibodies in AGS cell lines were used to detect miR-155-5p mRNA levels. (c) Western blot analysis of SMAD2 and SP1 transfected with miR-155-5p mimics and inhibitor. * p < 0.05; ** p < 0.01; *** p < 0.001.
Figure 5
Figure 5
CagA regulates malignant transformation through the miR-155-5p/SMAD2/SP1 axis in vitro. (a) Western blot analysis of SMAD2 and SP1 transfected with pcDNA-CagA. (b) Co-transfection of miR-155-5p mimics and pcDNA-CagA to investigate the level of SMAD2 and SP1 expression with Western blots in the AGS cell line. (c). Co-transfection of miR-155-5p inhibitors and pcDNA-CagA to investigate the levels of SMAD2 and SP1 expression with Western blots in the AGS cell line A: pcDNA-CagA + miR-155-5p mimics NC; B: pcDNA-CagA + miR-155-5p mimics; C: pcDNA-NC + miR-155-5p mimics; D: pcDNA-CagA + miR-155-5p inhibitors NC; E: pcDNA-CagA + miR-155-5p inhibitors; F: pcDNA-NC + miR-155-5p inhibitor; * p < 0.05; ** p < 0.01; *** p < 0.001.
Scheme 1
Scheme 1
General diagram summarizing the discovery and pathway.

Similar articles

Cited by

References

    1. Ishaq S., Nunn L. Helicobacter pylori and gastric cancer: A state of the art review. Gastroenterol. Hepatol. Bed Bench. 2015;8:6–14. - PMC - PubMed
    1. Plummer M., Franceschi S., Vignat J., Forman D., de Martel C. Global burden of gastric cancer attributable to Helicobacter pylori. Int. J. Cancer. 2015;136:487–490. doi: 10.1002/ijc.28999. - DOI - PubMed
    1. Backert S., Tegtmeyer N. Type IV Secretion and Signal Transduction of Helicobacter pylori CagA through Interactions with Host Cell Receptors. Toxins. 2017;9:115. doi: 10.3390/toxins9040115. - DOI - PMC - PubMed
    1. Bravo D., Hoare A., Soto C., Valenzuela M.A., Quest A.F. Helicobacter pylori in human health and disease: Mechanisms for local gastric and systemic effects. World J. Gastroenterol. 2018;24:3071–3089. doi: 10.3748/wjg.v24.i28.3071. - DOI - PMC - PubMed
    1. Plummer M., de Martel C., Vignat J., Ferlay J., Bray F., Franceschi S. Global burden of cancers attributable to infections in 2012: A synthetic analysis. Lancet Glob. Health. 2016;4:609–616. doi: 10.1016/S2214-109X(16)30143-7. - DOI - PubMed